IntegraGen: Decision expected on the divestment plan

On October 5, 2026, IntegraGen submitted two takeover bids to the Commercial Court of Évry as part of its receivership proceedings. Specializing in genomics for cancer and rare genetic diseases, the company received proposals from ABL Diagnostics and Health In Code for the acquisition of its operations and assets.

The court reserved its decision following the hearing, and the announcement is expected on October 9. None of the offers concern the repurchase of IntegraGen shares, leaving shareholders facing a potential risk of loss. Judicial liquidation could follow, resulting in delisting from the Euronext Growth Paris stock exchange.

IntegraGen continues its operations without interruption, with its teams fully mobilized to ensure the continuity of ongoing projects. The company is committed to keeping the market informed of upcoming developments.